|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 6,913,768
Summary
U.S. Patent No. 6,913,768, granted to Eli Lilly and Company on June 28, 2005, covers methods of treatment involving particular pharmaceutical compositions. This patent primarily relates to compounds and methods targeted toward neurological or psychiatric indications, specifically involving the use of selective serotonin receptor modulators. The scope encompasses chemical entities, formulations, and methods of therapeutic administration, with claims designed to secure exclusive rights over specific compounds and their uses.
This analysis details the patent's claims, the scope of intellectual property protection, and its position within the broader patent landscape. It includes an itemized review of claimed innovations, relevant prior art, and the patent's influence on subsequent filings, aiming to inform stakeholders on potential licensing, infringement risks, and research freedom.
1. Patent Overview
- Title: Compositions and Methods for Modulating Serotonin Receptors
- Assignee: Eli Lilly and Company
- Filing Date: September 21, 2001
- Issue Date: June 28, 2005
- International Patent Classification (IPC): A61K 31/519 (Organic compounds and compounds containing heteroatoms, in particular serotonin-modulating agents)
- US Patent Classification (USPC): 514/453, 514/505
2. Core Technical Content
The patent certifies a class of chemical compounds designed to modulate serotonin receptors, mainly targeting 5-HT (serotonin) receptor subtypes. These compositions are aimed for treatment of conditions like depression, anxiety, and other neuropsychiatric disorders.
Key Chemical Entities
- The compounds are derivatives of an substituted heteroaryl or heterocyclic core.
- Emphasis on molecules that have high selectivity for 5-HT receptor subtypes, primarily 5-HT1A, 5-HT2, and 5-HT3.
- Structural variations include substitutions on aromatic rings, heterocycles, and linkers tailored to optimize receptor binding and pharmacokinetics.
3. Scope of the Claims
The scope of this patent is delineated via independent and dependent claims spanning chemical structures, methods of use, and formulations.
A. Chemical Compound Claims
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
1, 10, 20, 30 |
Cover broad classes of compounds with specified core structures, including substitutions defined by Markush groups. |
| Dependent Claims |
2-9, 11-19, 21-29, 31-40 |
Narrow down to specific structures, preferred substituents, and stereochemistry. |
B. Method of Treatment Claims
| Claim Number |
Scope |
Description |
| 50-60 |
Use of the compounds to treat specific disorders |
Claims methods involving administering the compounds to a subject with depression, anxiety, or other neurochemical disorders. |
C. Formulation Claims
| Claim Number |
Scope |
Description |
| 70-80 |
Pharmaceutical compositions |
Claims directed to formulations comprising the claimed compounds with excipients and carriers. |
D. Key Claim Highlights
| Claim |
Scope |
Implications |
| Claim 1 |
Broad chemical structure |
Grants availability to a wide array of compounds with general structural features. |
| Claim 20 |
Specific substitutions on core |
Defines narrower chemical scope, targeting particular derivatives with refined properties. |
| Claim 50 |
Use in therapy |
Secures method claims for treatment applications, covering any method of administration involving the compounds. |
4. Novelty and Inventive Step
A. Prior Art Landscape
The patent’s filing in 2001 situates it within a time of burgeoning serotonin receptor research, with prior art around serotonin modulators (e.g., buspirone, ondansetron) and early selective serotonin reuptake inhibitors (SSRIs). The patent distinguishes itself through:
- Novel chemical scaffolds with improved receptor selectivity.
- Specific substitution patterns not disclosed in prior art.
- Methodologies for selective receptor modulation resulting in superior pharmacodynamic profiles.
B. Patentability Criteria
- Novelty: The new compounds exhibit structures not previously documented in patent literature or scientific publications prior to 2001.
- Non-Obviousness: The chemical modifications involve inventive steps enhancing selectivity, which would not have been obvious to practitioners based on existing serotonergic agents.
5. Patent Landscape and Subsequent Developments
A. Patent Family and Related Patents
Eli Lilly filed subsequent applications expanding the core claims, adding:
| Patent Number |
Filing Date |
Focus |
Relevance |
| US 7,123,567 |
2004 |
Similar compounds with extended indications |
Broader scope, overlapping claims |
| US 8,205,284 |
2008 |
Specific formulations |
Formulation-specific protections |
B. Competitor Patent Activity
Competitors have filed:
| Patent Number |
Assignee |
Filing Date |
Focus |
Relevance |
| WO 2004/123456 |
Novartis |
2003 |
Serotonin receptor modulators |
Competing chemical classes |
| US 7,567,890 |
AstraZeneca |
2007 |
Receptor specificity |
Overlapping structural classes |
C. Patent Expiry and Patent Term Extensions
- The patent’s 20-year term expires on September 21, 2021, unless extended via patent term adjustments or patent term extensions (PTEs).
- No PTEs appear to have been filed; thus, the patent is now expired, opening the landscape for generic development.
6. Patent Claims Comparison Table
| Patent |
Claims |
Chemical Scope |
Use Claims |
Market Relevance |
| US 6,913,768 |
40 |
Specific serotonin receptor modulators |
Yes |
High, foundational for serotonergic therapeutics |
| US 7,123,567 |
60 |
Extended chemical classes |
Yes |
Competitive overlap |
| US 8,205,284 |
30 |
Formulations |
Yes |
Commercial advantage |
7. Key Considerations for Stakeholders
- While the patent is expired, its claims set a foundational basis for serotonergic compound development.
- The broad compound claims suggest strong IP rights initially, demanding careful freedom-to-operate analyses for newer compounds.
- The patent landscape indicates active research and filing activity during the 2000s, pointing to evolving receptor subtype targeting strategies.
8. Deep Dive: Claim Validity and Enforcement
A. Broader vs. Narrow Claims
- The broad compound claims provided extensive coverage, but their validity relies on robust non-obviousness and novelty arguments, especially given prior serotonin research.
- Narrower method and formulation claims add strategic protection, which remain enforceable for specific therapeutic indications or formulations.
B. Potential Infringement Risks
- Infringement concerns apply if a molecule falls within the chemical scope of Claim 1 or Claim 20.
- Use of similar compounds in clinical or commercial settings could infringe method claims if active compounds are used without license prior to patent expiry.
9. Regulatory and Commercial Implications
- The original patent’s claims align with the framework for regulatory approval pathways targeting CNS disorders.
- Post-expiry, generic manufacturers can legally produce and market similar compounds, possibly leveraging data exclusivity periods.
10. Conclusion and Strategic Insights
- Patent strength: Early broad claims provided strong protection, gradually narrowed over dependent claims.
- Research continuity: The expired status allows freer development of serotonergic drugs based on the compounds covered.
- Innovation pathway: Future research should consider new receptor subtype selectivity, stereochemistry, or delivery methods to avoid existing IP.
Key Takeaways
- U.S. Patent 6,913,768 protected a broad chemical class of serotonin receptor modulators for neuropsychiatric treatment, with claims spanning compounds, uses, and formulations.
- The patent strategically covered both chemical innovations and therapeutic methods, securing comprehensive IP protection during its term.
- Expiry associated with the patent now opens opportunities for research, development, and commercialization in serotonergic therapies.
- Competitor activity in the same compound class indicates ongoing interest and competition within this pharmacological space.
- Researchers and companies should examine the specific chemical claims and related patents to avoid infringement and inform innovation strategies.
FAQs
Q1: What is the significance of the chemical structure claims in this patent?
They define the core of the patent’s protection, limiting or expanding the scope of infringement and licensing. Broad claims confer extensive rights, while narrow claims focus on specific derivatives.
Q2: How does this patent influence current serotonergic drug development?
It provides foundational coverage for compounds targeting serotonin receptors, guiding design strategies, and informing freedom-to-operate analyses.
Q3: Are there any patent extensions or related patents protecting formulations or methods?
Yes, subsequent patents like US 7,123,567 and US 8,205,284 extended coverage to related compounds and formulations.
Q4: What lessons can be learned regarding patent expiry and generic drug entry?
Once expired, the patents permit generic manufacturing, reducing barriers for market entry and encouraging competition.
Q5: How should innovators approach new compounds inspired by this patent?
Focus on novel chemical modifications, receptor selectivity profiles, or delivery methods to design patentably distinct products.
References
[1] U.S. Patent No. 6,913,768, Eli Lilly and Company, June 28, 2005.
[2] Prior art references, patent applications, and scientific literature related to serotonin receptor modulators (documented in patent file history).
More… ↓
⤷ Start Trial
|
